Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients
Authors:
Open Access
- 20 November 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (22) , 2656-2666
Abstract
The coronavirus disease 2019 (COVID-19) pandemic poses a great threat to public health. Individuals who are immunocompromised because of the progression of the primary disease or receiving immunosuppressive medications are prone to severe COVID-19 complications and poor outcomes. Abundant data have shown that many COVID-19 vaccines are safe and effective in large-scale populations; however, these clinical trials have excluded immunocompromised populations. Available evidence indicates that immunocompromised populations have a blunted immune response to other vaccines, raising concerns regarding the efficacy of COVID-19 vaccination in these populations. Thus, there is an urgent need to delineate the efficacy of COVID-19 vaccines in these vulnerable populations. Here, we review the characteristics of specific humoral and cellular responses to COVID-19 vaccination in immunocompromised populations, including HIV-infected patients and those receiving immunosuppressive treatment, especially solid organ transplant recipients and those undergoing anti-CD20 treatment. We also addressed the challenges that immunocompromised populations will face in the future pandemic and the need for basic and clinical translational studies to highlight the best vaccination strategies for these populations.Keywords
This publication has 87 references indexed in Scilit:
- HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platformThe Lancet HIV, 2021
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostNew England Journal of Medicine, 2020
- An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplantsKidney International, 2020
- Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort StudyClinical Infectious Diseases, 2020
- Determining risk factors for mortality in liver transplant patients with COVID-19The Lancet Gastroenterology & Hepatology, 2020
- COVID-19 in Immunocompromised Hosts: What We Know So FarClinical Infectious Diseases, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatmentAutoimmunity Highlights, 2017
- Influenza Vaccination in Immunocompromised Patients: Efficacy and SafetyImmunotherapy, 2014